Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Long-term efficacy of cyclical etidronate therapy in postmenopausal osteoporosis.

Heaney A, Steele I, Taggart H.

Ir J Med Sci. 1997 Oct-Dec;166(4):257-9.

PMID:
9394079
3.

Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.

Miller PD, Watts NB, Licata AA, Harris ST, Genant HK, Wasnich RD, Ross PD, Jackson RD, Hoseyni MS, Schoenfeld SL, Valent DJ, Chesnut CH 3rd.

Am J Med. 1997 Dec;103(6):468-76. Erratum in: m J Med 1998 Jun;104(6):608.

PMID:
9428829
4.

Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis.

Iwamoto J, Takeda T, Ichimura S, Uzawa M.

Keio J Med. 2003 Jun;52(2):113-9.

6.

Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures.

Anderson FH, Francis RM, Bishop JC, Rawlings DJ.

Age Ageing. 1997 Sep;26(5):359-65.

7.

Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy.

Cortet B, Béra-Louville A, Gauthier P, Gauthier A, Marchandise X, Delcambre B.

Joint Bone Spine. 2001 Oct;68(5):410-5.

PMID:
11707007
8.

Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis.

Storm T, Kollerup G, Thamsborg G, Genant HK, Sørensen OH.

J Rheumatol. 1996 Sep;23(9):1560-4.

PMID:
8877926
10.
11.

[The clinical benefits to bone mineral density were shown by cyclical oral etidronate administration in steroid induced osteoporosis].

Nakamura T, Maekawa S, Morinobu S, Morinobu A, Koshiba M, Yamauchi M, Sugimoto T, Kumagai S.

Ryumachi. 2002 Aug;42(4):666-75. Japanese.

PMID:
12355861
13.

Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.

Fogelman I, Herd RJ, Blake GM, Balena R.

Calcif Tissue Int. 2000 May;66(5):348-54.

PMID:
10773104
14.

Effects of combined treatment with etidronate, nandrolone-decanoate and calcium on bone mineral density in postmenopausal women.

Bolanca S, Korsić M, Dekanić D, Cvijetić S.

Acta Med Croatica. 1998;52(3):159-63.

PMID:
9818438
15.
16.

Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup.

Sato S, Ohosone Y, Suwa A, Yasuoka H, Nojima T, Fujii T, Kuwana M, Nakamura K, Mimori T, Hirakata M.

J Rheumatol. 2003 Dec;30(12):2673-9.

PMID:
14719212
17.

Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup.

Sato S, Takada T, Katsuki Y, Kimura N, Kaneko Y, Suwa A, Hirakata M, Kuwana M.

J Rheumatol. 2008 Jan;35(1):142-6. Epub 2007 Nov 15.

PMID:
18050368
18.

Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis.

Guañabens N, Parés A, Ros I, Alvarez L, Pons F, Caballería L, Monegal A, Martínez de Osaba MJ, Roca M, Peris P, Rodés J.

Am J Gastroenterol. 2003 Oct;98(10):2268-74.

PMID:
14572578
19.

The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: a four-year study.

Lyritis GP, Tsakalakos N, Paspati I, Skarantavos G, Galanos A, Androulakis C.

Clin Rheumatol. 1997 Jun;16(4):354-60.

PMID:
9259248
20.

Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.

Bonnick S, Broy S, Kaiser F, Teutsch C, Rosenberg E, DeLucca P, Melton M.

Curr Med Res Opin. 2007 Jun;23(6):1341-9.

PMID:
17594775
Items per page

Supplemental Content

Write to the Help Desk